Literature DB >> 21452155

The prognostic value of hydronephrosis in bladder cancer treated by radical cystectomy.

Huan-yi Lin1, Sheng-zheng Wang, Jun-xing Chen, Ling-wu Chen, Jun Xiao.   

Abstract

OBJECTIVES: To evaluate the prognostic impact of hydronephrosis in bladder cancer treated by radical cystectomy.
METHODS: We performed a retrospective review of 126 patients with transitional cell carcinoma of bladder, who underwent radical cystectomy at our hospital from January 2003 through May 2010. The relationship between hydronephrosis, tumor stage, and lymph node status was analyzed. We evaluated the effect of hydronephrosis on the recurrence-free survival of bladder cancer by using log-rank test and multivariate Cox regression analysis.
RESULTS: Thirty-four patients had unilateral hydronephrosis and five patients had bilateral hydronephrosis. There were 59.0% of tumors with stage ≥pT3a, and 30.8% with pT2, 10.2% with pT1 in the Hydronephrosis group respectively compared to 14.9%, 59.8%, and 25.3% in the Non-hydronephrosis group (χ2 = 25.680, P<0.001). The 5-year recurrence-free survival rates in the Hydronephrosis group were significantly lower than the Non-hydronephrosis group (42.5±10.3% vs. 68.8±8.1%, P=0.001). When adjusted to the different stages stratum, the recurrence-free survival rates among patients with stage pT1-2pN- or lymph node metastasis did not differ significantly whether they had evidence of preoperative hydronephrosis or not, while they differed significantly in the subgroup of stage ≥pT3a,pN-. Multivariate analysis showed that hydronephrosis was not an independent prognostic factor for recurrence-free survival except pathological stage and lymph node status.
CONCLUSIONS: Preoperative hydronephrosis predicts advanced stages in transitional cell carcinoma of bladder and exactly effects the survival mainly in higher stage tumor without metastasis.

Entities:  

Mesh:

Year:  2011        PMID: 21452155     DOI: 10.5301/ru.2011.6444

Source DB:  PubMed          Journal:  Urologia        ISSN: 0391-5603


  6 in total

1.  Preoperative chronic kidney disease before radical cystectomy as predictor of oncological outcomes: a pick of the iceberg?

Authors:  Fabio Zattoni; Alessandro Morlacco; Filiberto Zattoni
Journal:  World J Urol       Date:  2018-02-07       Impact factor: 4.226

2.  Influence of preoperative hydronephrosis on the outcome of urothelial carcinoma of the upper urinary tract after nephroureterectomy: the results from a multi-institutional French cohort.

Authors:  G Bozzini; L Nison; P Colin; A Ouzzane; D R Yates; F Audenet; G Pignot; A Arvin-Berod; O Merigot; L Guy; J Irani; F Saint; S Gardic; P Gres; F Rozet; Y Neuzillet; A Ruffion; M Roupret
Journal:  World J Urol       Date:  2012-10-11       Impact factor: 4.226

3.  Intraoperative hypothermia is a significant prognostic predictor of radical cystectomy especially for stage II muscle-invasive bladder cancer.

Authors:  Kento Morozumi; Koji Mitsuzuka; Yuki Takai; Yuki Katsumata; Akito Kuromoto; Senji Hoshi; Kenji Numahata; Yoichi Arai
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

4.  Preoperative predictors of early death risk in bladder cancer patients treated with robot-assisted radical cystectomy.

Authors:  Zhaowei Zhu; Xiaojing Wang; Jiange Wang; Shengzheng Wang; Yafeng Fan; Tianlong Fu; Songqiang Cao; Xuepei Zhang
Journal:  Cancer Med       Date:  2019-05-15       Impact factor: 4.452

5.  A population-based cohort study examining the association of documented bladder diverticulum and bladder cancer risk in urology patients.

Authors:  Chu-Wen Fang; Vivian Chia-Rong Hsieh; Steven Kuan-Hua Huang; I-Ju Tsai; Chih-Hsin Muo; Shih-Chi Wu
Journal:  PLoS One       Date:  2019-10-15       Impact factor: 3.240

6.  Prognostic value of preoperative hydronephrosis in patients with bladder cancer undergoing radical cystectomy: A meta-analysis.

Authors:  Zhaowei Zhu; Jia Zhao; Yinghui Li; Chen Pang; Zhanwei Zhu; Xuepei Zhang
Journal:  PLoS One       Date:  2019-09-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.